SWOG clinical trial number
S1403

A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone In Treatment-Naïve Patients With Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)

29% Accrual
Accrual
29%
Closed
Phase
29% Accrual
Accrual
29%
Abbreviated Title
Lung Ph II/III Stage IV NSCLC Afatinib+Cetuximab vs Afatinib
Status Notes
This study permanently closed to accrual effective April 23, 2018.
Activated
03/25/2015
Closed
04/23/2018
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lung Cancer

Treatment

Cetuximab Afatinib

Other Clinical Trials

S2414
SWOG Clinical Trial Number

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
0% Accrual
Accrual
0%
Open
Phase
A082002
SWOG Clinical Trial Number

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open